AI, Google and DeepMind

AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.
Google-backed, AI-developed drugs are headed to trial by 2026, DeepMind CEO says
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
Europe accelerates AI drug discovery as DeepMind spinoff targets trials this year
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll hopefully have
Trials of drugs developed with AI could begin this year, Google DeepMind CEO says
The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.
Google DeepMind CEO says 2025's the year we start popping pills AI helped invent
Nobel Prize winner Demis Hassabis thinks human trials will happen soon Clinical trials of the first drugs designed with the help of artificial intelligence could commence this year, Google DeepMind CEO Demis Hassabis suggested Tuesday.
DeepMind expects clinical trials for AI-designed drugs this year
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer. “We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Google's DeepMind eyes clinical trials for AI-designed drugs in 2025 - report
Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis. "We'll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Roll over, Darwin: How Google DeepMind's 'mind evolution' could enhance AI thinking
This new approach, based on natural selection, dramatically improves the reliability of large language models for practical ...
DeepMind’s new inference-time scaling technique improves planning accuracy in LLMs
With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.
Why AI Creatives Are Touting Google’s Veo 2 as Best Video Generation Model
AI creatives with access to Google’s Veo 2 text-to-video tool say it’s another “leap forward” for video generation Veo 2 ...
The Prompt: Inside Google's AI Innovation Engine
The order, signed in October 2023, required companies building powerful AI systems to share their safety test results with the federal government and come up with ways to limit their models’ biases ...
Wall Street Lunch: AI-Designed Drugs Expected To See Trials This Year
Google's DeepMind spinoff Isomorphic Labs expects clinical trials of drugs designed using AI to start late this year.
Nairametrics3d
Google offers fully funded AI science scholarships for African students
Google DeepMind AI for Science Scholarships are now available, offering African students the opportunity to pursue ...
NextBigFuture11h
Demis Hassabis Thinks Searching Knowledge Is Needed for Superintelligent AI
Demis Hassabis is the CEO of Google DeepMind. Demis thinks new agent type systems will be able to perform additional tree of knowledge search to achieve ...
Hosted on MSN1d
Google DeepMind COO on AI Regulation, Jobs, Trump
Google DeepMind Chief Operations Officer Lila Ibrahim discussed the changes that the Trump administration may bring, ...